136 related articles for article (PubMed ID: 30442938)
21. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
22. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
23. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
[TBL] [Abstract][Full Text] [Related]
27. Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma.
Heger U; Martens A; Schillings L; Walter B; Hartmann D; Hinz U; Pausch T; Giese N; Michalski CW; Hackert T
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010874
[TBL] [Abstract][Full Text] [Related]
28. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma.
Torphy RJ; Wang Z; True-Yasaki A; Volmar KE; Rashid N; Yeh B; Anderson JM; Johansen JS; Hollingsworth MA; Yeh JJ; Collisson EA
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30506016
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy and Radiofrequency-Induced Mild Hyperthermia Combined Treatment of Orthotopic Pancreatic Ductal Adenocarcinoma Xenografts.
Krzykawska-Serda M; Agha MS; Ho JC; Ware MJ; Law JJ; Newton JM; Nguyen L; Curley SA; Corr SJ
Transl Oncol; 2018 Jun; 11(3):664-671. PubMed ID: 29621664
[TBL] [Abstract][Full Text] [Related]
30. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer.
Piquemal D; Noguier F; Pierrat F; Bruno R; Cros J
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33143297
[TBL] [Abstract][Full Text] [Related]
31. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.
Isacoff WH; Cooper B; Bartlett A; McCarthy B; Yu KH
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740571
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
Tan E; El-Rayes B
J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
[TBL] [Abstract][Full Text] [Related]
34. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer.
Verdaguer H; Arroyo A; Macarulla T
Target Oncol; 2018 Dec; 13(6):691-704. PubMed ID: 30470972
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M
J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758
[TBL] [Abstract][Full Text] [Related]
36. ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling.
Pinho AV; Van Bulck M; Chantrill L; Arshi M; Sklyarova T; Herrmann D; Vennin C; Gallego-Ortega D; Mawson A; Giry-Laterriere M; Magenau A; Leuckx G; Baeyens L; Gill AJ; Phillips P; Timpson P; Biankin AV; Wu J; Rooman I
Nat Commun; 2018 Nov; 9(1):5083. PubMed ID: 30504844
[TBL] [Abstract][Full Text] [Related]
37. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
38. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
Yu KH; Ricigliano M; McCarthy B; Chou JF; Capanu M; Cooper B; Bartlett A; Covington C; Lowery MA; O'Reilly EM
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30477242
[TBL] [Abstract][Full Text] [Related]
39. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.
Yan H; Qiu W; Koehne de Gonzalez AK; Wei JS; Tu M; Xi CH; Yang YR; Peng YP; Tsai WY; Remotti HE; Miao Y; Su GH
Cancer Lett; 2019 Feb; 442():333-340. PubMed ID: 30447255
[TBL] [Abstract][Full Text] [Related]
40. Retraction: "Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis" by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J., and Wang, J.
J Cell Physiol; 2018 Nov; ():. PubMed ID: 30443987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
